{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:28:29Z","timestamp":1785295709465,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Die intravitreale operative Medikamenteneingabe (IVOM) ist weltweit die h\u00e4ufigste Therapieform bei Netzhautgef\u00e4\u00dferkrankungen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Untersuchung der Endophthalmitisrate sowie H\u00e4ufigkeit subjektiver Beschwerden und m\u00f6glicher Risikofaktoren im Zusammenhang mit IVOM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>In dieser monozentrischen Studie wurden im ersten Teil die Zahl der Endophthalmitisf\u00e4lle sowie potenzielle Risikofaktoren anhand der Routine-Krankenhausdokumentation von 123.373 IVOM im Zeitraum 2013 bis 2022 analysiert. Im zweiten Teil wurden subjektive Beschwerden sowie potenzielle Risikofaktoren nach IVOM anhand einer Umfrage mit 584 Patienten untersucht.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Von 2013 bis 2022 traten 27\u00a0Endophthalmitisf\u00e4lle nach IVOM auf (0,02\u202f%). Die Analyse potenzieller Risikofaktoren (Alter, Geschlecht, Desinfektionsart, Anzahl an Vorinjektionen, Wochentag, Jahr, beidseitige Injektion) zeigte, dass keiner dieser Faktoren mit einer erh\u00f6hten Endophthalmitisrate assoziiert war. Die anf\u00e4ngliche Identifikation der beidseitigen Injektion als Risikofaktor wurde durch weiterf\u00fchrende Analysen widerlegt und als statistisches Artefakt klassifiziert. Mehr als 10\u202f% der Patienten berichteten am Folgetag der Injektion \u00fcber Beschwerden wie Fremdk\u00f6rpergef\u00fchl (18\u202f%), Sehen von Luftblasen (17\u202f%), Juckreiz (12\u202f%) und ger\u00f6tetes Auge (11\u202f%). Seltener traten Hyposphagma (4\u202f%) oder starke Schmerzen am Tag nach der Injektion (2\u202f%) auf. M\u00e4nnliche Patienten berichteten seltener starke Schmerzen am Folgetag (Odds Ratio 0,18, 95\u202f%-Konfidenzintervall 0,03\u20130,72). Knapp 2\u202f% der Patienten suchten ungeplant einen Augenarzt auf oder erwogen einen Therapieabbruch aufgrund von Beschwerden.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diskussion<\/jats:title>\n            <jats:p>Subjektive Beschwerden treten h\u00e4ufiger auf als schwerwiegende Komplikationen und k\u00f6nnen die Therapieadh\u00e4renz gef\u00e4hrden. Eine Aufkl\u00e4rung \u00fcber erwartbare Missempfindungen ist sinnvoll.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00347-025-02222-w","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T14:13:16Z","timestamp":1743603196000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beschwerden und Komplikationen nach intravitrealer operativer Medikamenteneingabe (IVOM) und potenzielle Risikofaktoren","Complaints and complications after intravitreal injection (IVI) and potential risk factors"],"prefix":"10.1007","volume":"122","author":[{"given":"Lisa","family":"Prange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00fcrgen","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-1420","authenticated-orcid":false,"given":"Felicitas","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"2","key":"2222_CR1","doi-asserted-by":"publisher","first-page":"e0170988","DOI":"10.1371\/journal.pone.0170988","volume":"12","author":"J Birkh\u00e4uer","year":"2017","unstructured":"Birkh\u00e4uer\u00a0J, Gaab\u00a0J, Kossowsky\u00a0J et\u00a0al (2017) Trust in the health care professional and health outcome: A\u00a0meta-analysis. PLoS ONE 12(2):e170988. https:\/\/doi.org\/10.1371\/journal.pone.0170988","journal-title":"PLoS ONE"},{"issue":"1","key":"2222_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5301\/ejo.5001001","volume":"28","author":"S Doguizi","year":"2018","unstructured":"Doguizi\u00a0S, Sekeroglu\u00a0MA, Inanc\u00a0M et\u00a0al (2018) Evaluation of pain during intravitreal aflibercept injections. Eur J Ophthalmol 28(1):63\u201367. https:\/\/doi.org\/10.5301\/ejo.5001001","journal-title":"Eur J Ophthalmol"},{"key":"2222_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken\u00a0C, Helms\u00a0M, B\u00f6hringer\u00a0D et\u00a0al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"2222_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken\u00a0C, Ziemssen\u00a0F, Eter\u00a0N et\u00a0al (2020) Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol 258(10):2077\u20132090. https:\/\/doi.org\/10.1007\/s00417-020-04798-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2222_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0304-3959(91)90094-E","volume":"44","author":"JS Feine","year":"1991","unstructured":"Feine\u00a0JS, Bushnell\u00a0CM, Miron\u00a0D et\u00a0al (1991) Sex differences in the perception of noxious heat stimuli. Pain 44(3):255\u2013262. https:\/\/doi.org\/10.1016\/0304-3959(91)90094-E","journal-title":"Pain"},{"issue":"7","key":"2222_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"K Ghasemi Falavarjani","year":"2013","unstructured":"Ghasemi Falavarjani\u00a0K, Nguyen\u00a0QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a\u00a0review of literature. Eye 27(7):787\u2013794. https:\/\/doi.org\/10.1038\/eye.2013.107","journal-title":"Eye"},{"issue":"6","key":"2222_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1055\/s-0042-108584","volume":"80","author":"A Hajek","year":"2018","unstructured":"Hajek\u00a0A, Bock\u00a0J\u2011O, Saum\u00a0K\u2011U et\u00a0al (2018) Unterschiede in der Morbidit\u00e4t nach Krankenversichertenstatus im Alter. Gesundheitswesen 80(6):551\u2013556. https:\/\/doi.org\/10.1055\/s-0042-108584","journal-title":"Gesundheitswesen"},{"issue":"10326","key":"2222_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier\u00a0JS, Khanani\u00a0AM, Quezada Ruiz\u00a0C et\u00a0al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase\u00a03, non-inferiority trials. Lancet 399(10326):729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"issue":"5","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0031-1275711","volume":"74","author":"F Hoffmann","year":"2012","unstructured":"Hoffmann\u00a0F, Icks\u00a0A (2012) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen f\u00fcr die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 74(5):291\u2013297. https:\/\/doi.org\/10.1055\/s-0031-1275711","journal-title":"Gesundheitswesen"},{"issue":"8","key":"2222_CR10","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.12669\/pjms.38.8.5125","volume":"38","author":"IK Jeeva","year":"2022","unstructured":"Jeeva\u00a0IK, Masud\u00a0S, Siddiqui\u00a0MAR et\u00a0al (2022) Safety of simultaneous bilateral intravitreal versus unilateral anti-vasculo-endothelial growth factors injection in an operating room setting. Pak J Med Sci 38(8):2324\u20132330. https:\/\/doi.org\/10.12669\/pjms.38.8.5125","journal-title":"Pak J Med Sci"},{"key":"2222_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-531-91643-9_4","volume-title":"Gesundheitliche Ungleichheit","author":"M Jungbauer-Gans","year":"2009","unstructured":"Jungbauer-Gans\u00a0M, Gross\u00a0C (2009) Erkl\u00e4rungsans\u00e4tze sozial differenzierter Gesundheitschancen. In: Richter\u00a0M, Hurrelmann\u00a0K (Hrsg) Gesundheitliche Ungleichheit. VS, Wiesbaden, S\u00a077\u201398"},{"issue":"8","key":"2222_CR12","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim\u00a0LN, Mehta\u00a0H, Barthelmes\u00a0D et\u00a0al (2016) Metaanalysis of Real-World Outcomes of Intravitreal Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration. Retina 36(8):1418\u20131431. https:\/\/doi.org\/10.1097\/IAE.0000000000001142","journal-title":"Retina"},{"issue":"12","key":"2222_CR13","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00417-021-05302-0","volume":"259","author":"M Krauthammer","year":"2021","unstructured":"Krauthammer\u00a0M, Trabelsi\u00a0E, Moisseiev\u00a0E (2021) Intravitreal air bubbles following intravitreal injections: a\u00a0comprehensive analysis. Graefes Arch Clin Exp Ophthalmol 259(12):3697\u20133702. https:\/\/doi.org\/10.1007\/s00417-021-05302-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2222_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","volume":"29","author":"ID Ladas","year":"2009","unstructured":"Ladas\u00a0ID, Karagiannis\u00a0DA, Rouvas\u00a0AA et\u00a0al (2009) Safety of Repeat Intravitreal Injections of Bevacizumab Versus Ranibizumab. Retina 29(3):313\u2013318. https:\/\/doi.org\/10.1097\/IAE.0b013e31819a5f98","journal-title":"Retina"},{"key":"2222_CR15","doi-asserted-by":"publisher","first-page":"8567912","DOI":"10.1155\/2018\/8567912","volume":"2018","author":"PE Lau","year":"2018","unstructured":"Lau\u00a0PE, Jenkins\u00a0KS, Layton\u00a0CJ (2018) Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections. J\u00a0Ophthalmol 2018:8567912. https:\/\/doi.org\/10.1155\/2018\/8567912","journal-title":"J Ophthalmol"},{"issue":"1","key":"2222_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40942-021-00358-w","volume":"8","author":"A Miller","year":"2022","unstructured":"Miller\u00a0A, Wilneff\u00a0MA, Yazji\u00a0A et\u00a0al (2022) Analysis of urgent follow up visits and complications after intravitreal injections: a\u00a0retrospective cohort study. Int J Retin Vitreous 8(1):8. https:\/\/doi.org\/10.1186\/s40942-021-00358-w","journal-title":"Int J Retin Vitreous"},{"issue":"9","key":"2222_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/02713683.2012.681335","volume":"37","author":"E Moisseiev","year":"2012","unstructured":"Moisseiev\u00a0E, Regenbogen\u00a0M, Bartfeld\u00a0Y et\u00a0al (2012) Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res 37(9):813\u2013817. https:\/\/doi.org\/10.3109\/02713683.2012.681335","journal-title":"Curr Eye Res"},{"issue":"5","key":"2222_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1370\/afm.2554","volume":"18","author":"RH Olaisen","year":"2020","unstructured":"Olaisen\u00a0RH, Schluchter\u00a0MD, Flocke\u00a0SA et\u00a0al (2020) Assessing the Longitudinal Impact of Physician-Patient Relationship on Functional Health. Ann Fam Med 18(5):422\u2013429. https:\/\/doi.org\/10.1370\/afm.2554","journal-title":"Ann Fam Med"},{"issue":"9","key":"2222_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/02713683.2021.1874023","volume":"46","author":"M Pancholy","year":"2021","unstructured":"Pancholy\u00a0M, Storey\u00a0PP, Levin\u00a0HJ et\u00a0al (2021) Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a\u00a09-Year Period. Curr Eye Res 46(9):1370\u20131377. https:\/\/doi.org\/10.1080\/02713683.2021.1874023","journal-title":"Curr Eye Res"},{"issue":"7","key":"2222_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","volume":"5","author":"MS Ramos","year":"2021","unstructured":"Ramos\u00a0MS, Xu\u00a0LT, Singuri\u00a0S et\u00a0al (2021) Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors. Ophthalmol Retina 5(7):625\u2013632. https:\/\/doi.org\/10.1016\/j.oret.2020.09.024","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"2222_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3928\/23258160-20210528-04","volume":"52","author":"DP Reyes-Capo","year":"2021","unstructured":"Reyes-Capo\u00a0DP, Yannuzzi\u00a0NA, Smiddy\u00a0WE et\u00a0al (2021) Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a\u00a0Tertiary Referral Center. Ophthalmic Surg Lasers Imaging Retina 52(6):319\u2013326. https:\/\/doi.org\/10.3928\/23258160-20210528-04","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"2222_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IAE.0b013e3180307271","volume":"27","author":"IU Scott","year":"2007","unstructured":"Scott\u00a0IU, Flynn\u00a0HW (2007) Reducing the risk of endophthalmitis following intravitreal injections. Retina 27(1):10\u201312. https:\/\/doi.org\/10.1097\/IAE.0b013e3180307271","journal-title":"Retina"},{"issue":"6","key":"2222_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.5301\/EJO.2011.6482","volume":"21","author":"MA Shah","year":"2011","unstructured":"Shah\u00a0MA, Shah\u00a0SM, Shah\u00a0SB et\u00a0al (2011) Effect of interval between time of injury and timing of intervention on final visual outcome in cases of traumatic cataract. Eur J Ophthalmol 21(6):760\u2013765. https:\/\/doi.org\/10.5301\/EJO.2011.6482","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2222_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad\u00a0H, Mahmood\u00a0S, McGee\u00a0S et\u00a0al (2023) Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a\u00a0systematic review and meta-analysis. Syst Rev 12(1):92. https:\/\/doi.org\/10.1186\/s13643-023-02261-x","journal-title":"Syst Rev"},{"issue":"3","key":"2222_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0042-104583","volume":"79","author":"J Stauder","year":"2017","unstructured":"Stauder\u00a0J, Kossow\u00a0T (2017) Selektion oder bessere Leistungen \u2013 Warum sind Privatversicherte ges\u00fcnder als gesetzlich Versicherte? Gesundheitswesen 79(3):181\u2013187. https:\/\/doi.org\/10.1055\/s-0042-104583","journal-title":"Gesundheitswesen"},{"issue":"1\u20132","key":"2222_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pain.2009.05.018","volume":"145","author":"J Strong","year":"2009","unstructured":"Strong\u00a0J, Mathews\u00a0T, Sussex\u00a0R et\u00a0al (2009) Pain language and gender differences when describing a\u00a0past pain event. Pain 145(1\u20132):86\u201395. https:\/\/doi.org\/10.1016\/j.pain.2009.05.018","journal-title":"Pain"},{"key":"2222_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2147\/OPTH.S24358","volume":"5","author":"R Tailor","year":"2011","unstructured":"Tailor\u00a0R, Beasley\u00a0R, Yang\u00a0Y et\u00a0al (2011) Evaluation of patients\u2019 experiences at different stages of the intravitreal injection procedure\u2014what can be improved? Clin Ophthalmol 5:1499\u20131502. https:\/\/doi.org\/10.2147\/OPTH.S24358","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"2222_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/1120672120902028","volume":"31","author":"S Torres-Costa","year":"2021","unstructured":"Torres-Costa\u00a0S, Ramos\u00a0D, Brand\u00e3o\u00a0E et\u00a0al (2021) Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol 31(2):600\u2013606. https:\/\/doi.org\/10.1177\/1120672120902028","journal-title":"Eur J Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:55:08Z","timestamp":1749729308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02222-w","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Prange, D.\u00a0B\u00f6hringer, T.\u00a0Reinhard, H.\u00a0Agostini und F.\u00a0Bucher geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}